Physiological targeting to improve anticancer drug selectivity

被引：18

作者：

Hambley, Trevor W. ^{[1
]}

机构：

[1] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia

来源：

AUSTRALIAN JOURNAL OF CHEMISTRY | 2008年 / 61卷 / 09期

关键词：

D O I：

10.1071/CH08180

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The physiological differences between solid tumours and the healthy tissues and organs of the body are both an impediment to effective treatment and a potential basis for targeting strategies. In the present review, we outline the physiological features that distinguish tumours including hypoxia, acidity, and inhibited transport and describe the strategies being employed to exploit these differences in order to generate more selective and less toxic anticancer agents.

引用

页码：647 / 653

页数：7

共 94 条

[1] Bacteriolytic therapy can generate a potent immune response against experimental tumors [J].

Agrawal, N ;

Bettegowda, C ;

Cheong, I ;

Geschwind, JF ;

Drake, CG ;

Hipkiss, EL ;

Tatsumi, M ;

Dang, LH ;

Diaz, LA ;

Pomper, M ;

Abusedera, M ;

Wahl, RL ;

Kinzler, KW ;

Zhou, SB ;

Huso, DL ;

Vogelstein, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (42) :15172-15177

[2] Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both Platinum(II) and Platinum(IV) complexes [J].

Alderden, Rebecca A. ;

Mellor, Howard R. ;

Modok, Szabolcs ;

Hall, Matthew D. ;

Sutton, Stephen R. ;

Newville, Matthew G. ;

Callaghan, Richard ;

Hambley, Trevor W. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (44) :13400-+

[3]

Anderson R F, 1996, Br J Cancer Suppl, V27, pS48

[4] Mitochondria: a target for cancer therapy [J].

Armstrong, JS .

BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 (03) :239-248

[5] Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts [J].

Baker, Jennifer H. E. ;

Lindquist, Kirstin E. ;

Huxham, LynseyA. ;

Kyle, Alastair H. ;

Sy, Jonathan T. ;

Minchinton, Andrew I. .

CLINICAL CANCER RESEARCH, 2008, 14 (07) :2171-2179

[6] Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents [J].

Berners-Price, SJ ;

Bowen, RJ ;

Galettis, P ;

Healy, PC ;

McKeage, MJ .

COORDINATION CHEMISTRY REVIEWS, 1999, 185-6 :823-836

[7] Towards new transition metal-based hypoxic selective agents for therapy and imaging [J].

Blower, PJ ;

Dilworth, JR ;

Maurer, RI ;

Mullen, GD ;

Reynolds, CA ;

Zheng, YF .

JOURNAL OF INORGANIC BIOCHEMISTRY, 2001, 85 (01) :15-22

[8]

Brown JM, 1998, CANCER RES, V58, P1408

[9] Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases [J].

Carde, P ;

Timmerman, R ;

Mehta, MP ;

Koprowski, CD ;

Ford, J ;

Tishler, RB ;

Miles, D ;

Miller, RA ;

Renschler, MF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :2074-2083

[10] In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy [J].

Conway, Clare L. ;

Walker, Ian ;

Bell, Andrea ;

Roberts, David J. H. ;

Brown, Stanley B. ;

Vernon, David I. .

PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2008, 7 (03) :290-298

← 1 2 3 4 5 6 7 8 9 10 →